FIELD: medicine.
SUBSTANCE: group of inventions discloses methods of detecting and/or inhibition TOR-kinase activity in patients, including measurement by flow cytometry amount phosphorylated 4EVR1 in patient biological sample before and after introduction of TOR-kinase inhibitor, where TOR-kinase inhibitor represents 7-(6-(2-hydroxypropane-2-yl)pyridine-3-yl)-1-(trans-4-methoxycyclohexyl)-3,4-dihydropirazino[2,3-b]pyrazine-2(1H)-on, or 1-ethyl-7-(2-methyl-6-(4H-1,2,4-triazole-3-yl)pyridine-3-yl)-3,4-dihydropirazino[2,3-b]pyrazine-2(1H)-on or its pharmaceutically acceptable salt, stereoisomer or tautomer, as well as kit for use in flow cytometry for detecting or measuring TOR-kinase activity inhibition in patient.
EFFECT: group of measurements is effective in measuring and/or detecting of inhibition TOR-kinase activity.
5 cl, 6 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IDENTIFICATION OF LKB1 MUTATION AS PROGNOSTIC BIOMARKER OF SENSITIVITY TO TOR-KINASE INHIBITORS | 2011 |
|
RU2565034C2 |
| METHODS OF OBTAINING AND PURIFICATION OF HETEROARYL COMPOUNDS | 2010 |
|
RU2557242C2 |
| MTOR KINASE INHIBITORS FOR ONCOLOGIC INDICATIONS AND DISEASES ASSOCIATED WITH MTOR/PI3K/AKT BY METABOLISM | 2009 |
|
RU2692796C2 |
| mTOR KINASE INHIBITORS FOR ONCOLOGICAL INDICATIONS AND DISEASES METABOLICALLY BOUND TO mTOR/PI3K/AKT | 2009 |
|
RU2546658C2 |
| HETEROARYL COMPOUNDS, COMPOSITIONS CONTAINING THEM AND METHODS OF TREATING WITH USE OF SUCH COMPOUNDS | 2007 |
|
RU2478635C2 |
| AMINOTRIAZOLOPYRIDINES AND USING THEM AS KINASE INHIBITORS | 2009 |
|
RU2552642C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788174C2 |
| IMIDAZOTRIAZINONE COMPOUNDS | 2011 |
|
RU2603140C2 |
| METHODS AND MEDICAL APPLICATIONS | 2018 |
|
RU2788163C2 |
| SPIROCYCLIC AZAINDOLE DERIVATIVES | 2007 |
|
RU2468028C2 |
